{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:17Z","timestamp":1794255857238,"version":"4.9.0"},"reference-count":34,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The role of U300 glargine insulin for the inpatient management of type 2 diabetes (T2D) has not been determined. We compared the safety and efficacy of glargine U300 versus glargine U100 in noncritically ill patients with T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This prospective, open-label, randomized clinical trial included 176 patients with poorly controlled T2D (admission blood glucose [BG] 228 \u00b1 82 mg\/dL and HbA1c 9.5 \u00b1 2.2%), treated with oral agents or insulin before admission. Patients were treated with a basal-bolus regimen with glargine U300 (n = 92) or glargine U100 (n = 84) and glulisine before meals. We adjusted insulin daily to a target BG of 70\u2013180 mg\/dL. The primary end point was noninferiority in the mean difference in daily BG between groups. The major safety outcome was the occurrence of hypoglycemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>There were no differences between glargine U300 and U100 in mean daily BG (186 \u00b1 40 vs. 184 \u00b1 46 mg\/dL, P = 0.62), percentage of readings within target BG of 70\u2013180 mg\/dL (50 \u00b1 27% vs. 55 \u00b1 29%, P = 0.3), length of stay (median [IQR] 6.0 [4.0, 8.0] vs. 4.0 [3.0, 7.0] days, P = 0.06), hospital complications (6.5% vs. 11%, P = 0.42), or insulin total daily dose (0.43 \u00b1 0.21 vs. 0.42 \u00b1 0.20 units\/kg\/day, P = 0.74). There were no differences in the proportion of patients with BG &amp;lt;70 mg\/dL (8.7% vs. 9.5%, P &amp;gt; 0.99), but glargine U300 resulted in significantly lower rates of clinically significant hypoglycemia (&amp;lt;54 mg\/dL) compared with glargine U100 (0% vs. 6.0%, P = 0.023).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Hospital treatment with glargine U300 resulted in similar glycemic control compared with glargine U100 and may be associated with a lower incidence of clinically significant hypoglycemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-1940","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:06:26Z","timestamp":1586477186000},"page":"1242-1248","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":37,"title":["A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03013985","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03877068","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03832907","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03508934","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03013985","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03078478","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-6703","authenticated-orcid":false,"given":"Francisco J.","family":"Pasquel","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7364-5550","authenticated-orcid":false,"given":"M. Cecilia","family":"Lansang","sequence":"additional","affiliation":[{"name":"The Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Khowaja","sequence":"additional","affiliation":[{"name":"Hennepin County Medical Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Agustina","family":"Urrutia","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumeth","family":"Cardona","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Albury","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-3160","authenticated-orcid":false,"given":"Maya","family":"Fayfman","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Davis","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Migdal","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-015X","authenticated-orcid":false,"given":"Priyathama","family":"Vellanki","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Peng","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"2022031300330262100_B1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300330262100_B2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.290.15.2041","article-title":"Glucose control and mortality in critically ill patients","volume":"290","author":"Finney","year":"2003","journal-title":"JAMA"},{"key":"2022031300330262100_B3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.CCM.0000045568.12881.10","article-title":"Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control","volume":"31","author":"Van den Berghe","year":"2003","journal-title":"Crit Care Med"},{"key":"2022031300330262100_B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/014860719802200277","article-title":"Early postoperative glucose control predicts nosocomial infection rate in diabetic patients","volume":"22","author":"Pomposelli","year":"1998","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2022031300330262100_B5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2022031300330262100_B6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300330262100_B7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/jc.2008-1441","article-title":"Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine Hagedorn plus regular in medical patients with type 2 diabetes","volume":"94","author":"Umpierrez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300330262100_B8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.amjmed.2006.05.070","article-title":"Sliding scale insulin use: myth or insanity","volume":"120","author":"Umpierrez","year":"2007","journal-title":"Am J Med"},{"key":"2022031300330262100_B9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B11","first-page":"S11","article-title":"Standards of Medical Care in Diabetes\u20142012. In Clinical Practice Recommendations, 2012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B12","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diabet.2015.11.005","article-title":"The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation","volume":"42","author":"Monnier","year":"2016","journal-title":"Diabetes Metab"},{"key":"2022031300330262100_B14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1060028015597915","article-title":"New insulin glargine 300 U\/mL for the treatment of type 1 and type 2 diabetes mellitus","volume":"49","author":"Goldman","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2022031300330262100_B15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2146\/ajhp150174","article-title":"Insulin glargine 300 units\/mL: a new basal insulin product for diabetes mellitus","volume":"73","author":"Clements","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"2022031300330262100_B16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/dom.12472","article-title":"One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U\/ml compared with 100 U\/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension","volume":"17","author":"Riddle","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031300330262100_B17","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/dom.12532","article-title":"Glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus insulin glargine 100 U\/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension","volume":"17","author":"Yki-J\u00e4rvinen","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031300330262100_B19","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031300330262100_B21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/dc09-0169","article-title":"Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial","volume":"32","author":"Umpierrez","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/dc16-2215","article-title":"Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"40","author":"International Hypoglycaemia Study Group","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","article-title":"Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial","volume":"5","author":"Pasquel","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300330262100_B25","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc12-1988","article-title":"Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B26","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1111\/dom.13470","article-title":"Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U\/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment","volume":"20","author":"Javier Escalada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031300330262100_B27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1507\/endocrj.EJ18-0309","article-title":"Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study","volume":"66","author":"Suzuki","year":"2019","journal-title":"Endocr J"},{"key":"2022031300330262100_B28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1932296819841585","article-title":"Efficacy and safety of degludec compared to glargine 300 units\/mL in insulin-experienced patients with type 2 diabetes: trial protocol amendment (NCT03078478)","volume":"13","author":"Philis-Tsimikas","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"2022031300330262100_B29","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.2337\/dc15-1835","article-title":"Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes","volume":"38","author":"Pasquel","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B30","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13587","article-title":"Glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicenter randomized clinical trial","author":"Vellanki","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022031300330262100_B31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-019-1184-8","article-title":"Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes","volume":"19","author":"Pasquel","year":"2019","journal-title":"Curr Diab Rep"},{"key":"2022031300330262100_B32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/dc18-1760","article-title":"A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes","volume":"42","author":"Fayfman","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300330262100_B33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcjd.2017.06.007","article-title":"TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units\/mL","volume":"41","author":"Yale","year":"2017","journal-title":"Can J Diabetes"},{"key":"2022031300330262100_B34","doi-asserted-by":"crossref","DOI":"10.2337\/db19-908-P","article-title":"908-P: Accuracy comparison of the Freestyle Libre Pro continuous glucose monitoring (CGM) and point-of-care (POC) testing in noncritically ill hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen","volume-title":"Diabetes","author":"Galindo","year":"2019"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-1940","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/6\/1242\/630242\/dc191940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/6\/1242\/630242\/dc191940.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:50:41Z","timestamp":1647143441000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/6\/1242\/35666\/A-Randomized-Controlled-Trial-Comparing-Glargine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,9]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-1940","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}